PET Approved Tracers - NMTCB 2024
- PET radiopharmaceuticals approved for neuroendocrine tumor images (note somatostatin receptors - SSTR)
- 68Ga-DOTATATE (FDA approval 2016)
- 68Ga-DOTATOC (FDG approval 2019) - DOTATOC "mirrors" DOTANOC1
- 64Cu-DOTATATE (FDG approval 2020)
- SSTR is over expressed in neuroendocrine tumors (NET) and has improved tumor localization and shorter imaging times when compare to Octreotide
Link
- SSTR level show different differentiation levels1
- Ki-67 staining/cell differentiation/
- Grade 1: <2% ki-67 staining
- Grade 2: 3 - 20% ki-67 staining
- Grade 3: 20% ki-67 staining
- Poorly-differentiation >55% G3 usually has a loss of SSTR and is more metabolically active. Which images represent this type of tumor?
- Well differentiated NECs tend to have greater SSRT
- Comparing the betas energies
- 64Cu beta particles has a max energy and range of 1.9 meV and 3.5 mm
- Half-life of 12.7 hours
- Has a lower photon yield with greater radiation dosimetry
- 68Ga beta particle has a max energy and range of 0.65 meV and 0.56 mm
- Half-life of 1.1 hour
- Higher photon yield with a lower radiation dosimetry
- Here are four different patient with NET that were given both radiopharmaceuticals that show similar results. At present there appears to be evidence that one is better than the other2
- Procedure
- Patient Prep
- D/C short acting somatostatin 12 hours prior to the exam
- D/C long acting somatostatin 3 to 4 weeks, however, research indicates that this may not be necessary1
- Patient should be well hydrated and continue with liquid intake up to one hour after the procedure
- Dose - EANM suggests
- 68Ga-DOTATOC- 3 to 5 mCi
- 8Ga-DOTATATE - 0.054 mCi/kg and up to 5.4 mCi
- 64Cu-DOTATATE - 4 mCi
- Uptake time
- 68Ga-DOTATOC, start scanning 55-90 minutes
- 68Ga-DOTATATE start scanning 40-90 minutes
- 64Cu-DOTATATE start scanning at 45-90 minutes
- Area of scan can either be head to toe or skull base to mid-thigh
Return to Table of Content
NMMI Procedures Standards/EANM Practice Guideline for SSTR
1
Choice Is Good at Times: The Emergence of [64Cu]Cu-DOTATATE–Based Somatostatin Receptor Imaging in the Era of [68Ga]Ga-DOTATATE by Jha, A, et al. JNMT (2022)2